Additional file 3: Figure S2. of Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever

Short form-36 (SF-36) physical component summary (PCS) and mental component summary (MCS) scores during the treatment and follow-up periods. EOS end of study. (DOCX 53 kb

Additional file 1: Table S1. of Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever

Demographics and baseline characteristics of the patients with familial Mediterranean fever (FMF) during the enrollment into the treatment period (n = 9). CRP C-reactive protein, ESR erythrocyte sedimentation rate, SAA serum amyloid A. (DOCX 16 kb

Additional file 1: of Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy

Table S1 Definition of adapted ACR JIA response. Table S2 Genes with ≥3-fold differential expression between patients with SJIA and healthy controls, prior to canakinumab treatment. Table S3 List of independent ethics committees or institutional review boards (trial 1). Table S4 List of independent ethics committees or institutional review boards (trial 2). (DOCX 53 kb